158 related articles for article (PubMed ID: 37192755)
1. Tandem versus single haematopoietic stem cell transplant and BV maintenance in relapsed/refractory Hodgkin lymphoma: A matched cohort analysis from the LYSA.
Marouf A; Molinari N; Sibon D; Cottereau AS; Kanoun S; Antoine C; Debureaux PE; Cavalieri D; Fornecker LM; Casasnovas RO; Herbaux C; Amorim S; Rossi C; Bouscary D; Brice P; Ghesquieres H; Tamburini J; Deau B
Br J Haematol; 2023 Jul; 202(2):379-383. PubMed ID: 37192755
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of four cycles of Brentuximab Vedotin as consolidation after autologous peripheral stem cell transplantation in relapsed/refractory Hodgkin lymphoma.
Kort J; Chidiac A; El Sayed R; Massoud R; Nehme R; Bazarbachi A; El-Cheikh J
Leuk Lymphoma; 2020 Jul; 61(7):1732-1735. PubMed ID: 32090673
[TBL] [Abstract][Full Text] [Related]
3. Brentuximab vedotin consolidation therapy after autologous stem-cell transplantation in patients with high-risk Hodgkin lymphoma: Multicenter retrospective study.
Akay OM; Ozbalak M; Pehlivan M; Yildiz B; Uzay A; Yigenoglu TN; Elverdi T; Kaynar L; Ayyildiz O; Yonal Hindilerden I; Goksoy HS; Izmir Guner S; Gunes AK; Sonmez M; Kurt Yuksel M; Civriz Bozdag S; Ozkurt ZN; Toptas T; Dogu MH; Salim O; Saydam G; Yavasoglu I; Ayli M; Ozet G; Albayrak M; Birtas Atesoglu E; Toprak SK; Yildirim R; Mehtap O; Kalayoglu Besisik S; Nalcaci M; Altuntas F; Ferhanoglu B
Hematol Oncol; 2021 Oct; 39(4):498-505. PubMed ID: 34171130
[TBL] [Abstract][Full Text] [Related]
4. Impact of pre- and/or post-autologous stem cell transplantation exposure to brentuximab vedotin on survival outcomes in patients with high-risk Hodgkin lymphoma.
Martínez C; de Haro ME; Romero S; Gutiérrez A; Domingo-Domènech E; González-Rodríguez AP; Zeberio I; Martínez-Badas MP; Rodríguez-Izquierdo A; Carpio C; Bastos-Oreiro M; Hernández-Rivas JÁ; Vallansot R; Kelleher N; Díaz-Gálvez FJ; Torrado T; Pereira A; García-Sanz R;
Ann Hematol; 2023 Feb; 102(2):429-437. PubMed ID: 36370191
[TBL] [Abstract][Full Text] [Related]
5. Brentuximab vedotin consolidation after autologous stem cell transplantation for Hodgkin lymphoma: A Fondazione Italiana Linfomi real-life experience.
Massaro F; Pavone V; Stefani PM; Botto B; Pulsoni A; Patti C; Cantonetti M; Visentin A; Scalzulli PR; Rossi A; Galimberti S; Cimminiello M; Gini G; Musso M; Sorio M; Arcari A; Zilioli VR; Luppi M; Mannina D; Fabbri A; Pietrantuono G; Annibali O; Tafuri A; Prete E; Mulè A; Barbolini E; Marcheselli L; Luminari S; Merli F
Hematol Oncol; 2022 Feb; 40(1):31-39. PubMed ID: 34694649
[TBL] [Abstract][Full Text] [Related]
6. Brentuximab vedotin as salvage treatment in Hodgkin lymphoma naïve transplant patients or failing ASCT: the real life experience of Rete Ematologica Pugliese (REP).
Pavone V; Mele A; Carlino D; Specchia G; Gaudio F; Perrone T; Mazza P; Palazzo G; Guarini A; Loseto G; Eleonora P; Cascavilla N; Scalzulli P; Melpignano A; Quintana G; Di Renzo N; Tarantini G; Capalbo S
Ann Hematol; 2018 Oct; 97(10):1817-1824. PubMed ID: 30054707
[TBL] [Abstract][Full Text] [Related]
7. Improved survival of autologous stem cell transplantation in primary refractory and relapsed Hodgkin lymphoma in the brentuximab vedotin era - real-world data from Hungary.
Husi K; Szabó R; Pinczés LI; Földeák D; Dudley R; Szomor Á; Koller B; Gopcsa L; Illés Á; Miltényi Z
Ann Hematol; 2023 Sep; 102(9):2555-2563. PubMed ID: 37428200
[TBL] [Abstract][Full Text] [Related]
8. Salvage treatment for relapsed/refractory Hodgkin lymphoma: role of allografting, brentuximab vedotin and newer agents.
Martino M; Festuccia M; Fedele R; Console G; Cimminiello M; Gavarotti P; Bruno B
Expert Opin Biol Ther; 2016; 16(3):347-64. PubMed ID: 26652934
[TBL] [Abstract][Full Text] [Related]
9. A targeted salvage therapy with Brentuximab vedotin in heavily treated refractory or relapsed pediatric Hodgkin lymphoma patients before and after stem cell transplantation.
Taçyıldız N; Tanyıldız HG; Ünal E; Dinçaslan H; Asarcıklı F; Aksoy BA; Vatansever G; Yavuz G
Turk J Pediatr; 2019; 61(5):671-676. PubMed ID: 32104998
[TBL] [Abstract][Full Text] [Related]
10. Brentuximab vedotin compared with other therapies in relapsed/refractory Hodgkin lymphoma post autologous stem cell transplant: median overall survival meta-analysis.
Bonthapally V; Yang H; Ayyagari R; Tan RD; Cai S; Wu E; Gautam A; Chi A; Huebner D
Curr Med Res Opin; 2015; 31(7):1377-89. PubMed ID: 25950500
[TBL] [Abstract][Full Text] [Related]
11. Brentuximab Vedotin in Transplant-Naïve Relapsed/Refractory Hodgkin Lymphoma: Experience in 30 Patients.
Zinzani PL; Pellegrini C; Cantonetti M; Re A; Pinto A; Pavone V; Rigacci L; Celli M; Broccoli A; Argnani L; Pulsoni A
Oncologist; 2015 Dec; 20(12):1413-6. PubMed ID: 26500229
[TBL] [Abstract][Full Text] [Related]
12. Positive impact of brentuximab vedotin on overall survival of patients with classical Hodgkin lymphoma who relapse or progress after autologous stem cell transplantation: A nationwide analysis.
Tsirigotis P; Vassilakopoulos T; Batsis I; Bousiou Z; Gkirkas K; Sakellari I; Kaloyannidis P; Roussou P; Pangalis GA; Moschogiannis M; Vassilopoulos G; Repousis P; Megalakaki A; Michalis E; Kalpadakis C; Papadaki HA; Kotsianidis I; Hatzimichael E; Spyridonidis A; Anargyrou K; Poulakidas E; Giannoullia P; Apostolidis I; Stamouli M; Konstantopoulos K; Pappa V; Panayiotidis P; Harhalakis N; Anagnostopoulos A; Angelopoulou M
Hematol Oncol; 2018 Oct; 36(4):645-650. PubMed ID: 29882363
[TBL] [Abstract][Full Text] [Related]
13. Results of a multicentre UK-wide retrospective study evaluating the efficacy of brentuximab vedotin in relapsed, refractory classical Hodgkin lymphoma in the transplant naive setting.
Eyre TA; Phillips EH; Linton KM; Arumainathan A; Kassam S; Gibb A; Allibone S; Radford J; Peggs K; Burton C; Stewart G; LeDieu R; Booth C; Osborne WL; Miall F; Eyre DW; Ardeshna KM; Collins GP
Br J Haematol; 2017 Nov; 179(3):471-479. PubMed ID: 28857136
[TBL] [Abstract][Full Text] [Related]
14. Brentuximab vedotin followed by allogeneic transplantation as salvage regimen in patients with relapsed and/or refractory Hodgkin's lymphoma.
Garciaz S; Coso D; Peyrade F; Fürst S; Duran S; Chetaille B; Brenot-Rossi I; Devillier R; Granata A; Blaise D; Bouabdallah R
Hematol Oncol; 2014 Dec; 32(4):187-91. PubMed ID: 24301099
[TBL] [Abstract][Full Text] [Related]
15. Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous transplant: meta-analysis versus historical data.
Bonthapally V; Wu E; Macalalad A; Yang H; Shonukan O; Liu Y; Chi A; Huebner D
Curr Med Res Opin; 2015 May; 31(5):993-1001. PubMed ID: 25772232
[TBL] [Abstract][Full Text] [Related]
16. Tandem haematopoietic stem cell transplantation for High Risk relapsed/refractory Hodgkin Lymphoma: a LYSA study.
Deau B; Amorim S; Perrot A; Quittet P; Cornillon J; Chaoui D; Marolleau JP; Oberic L; Le Du K; Fornecker LM; Tournilhac O; Veillard AS; Chaillol I; Robin M; Tamburini J; Brice P
Br J Haematol; 2018 May; 181(3):341-349. PubMed ID: 29611187
[TBL] [Abstract][Full Text] [Related]
17. Brentuximab vedotin in transplant-naive patients with relapsed or refractory hodgkin lymphoma: analysis of two phase I studies.
Forero-Torres A; Fanale M; Advani R; Bartlett NL; Rosenblatt JD; Kennedy DA; Younes A
Oncologist; 2012; 17(8):1073-80. PubMed ID: 22855426
[TBL] [Abstract][Full Text] [Related]
18. Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma. The Hellenic experience.
Angelopoulou MK; Vassilakopoulos TP; Batsis I; Sakellari I; Gkirkas K; Pappa V; Giannoulia P; Apostolidis I; Apostolopoulos C; Roussou P; Panayiotidis P; Dimou M; Kyrtsonis MC; Palassopoulou M; Vassilopoulos G; Moschogiannis M; Kalpadakis C; Margaritis D; Spyridonidis A; Michalis E; Anargyrou K; Repousis P; Hatzimichael E; Bousiou Z; Poulakidas E; Grentzelias D; Harhalakis N; Pangalis GA; Anagnostopoulos A; Tsirigotis P
Hematol Oncol; 2018 Feb; 36(1):174-181. PubMed ID: 28219112
[TBL] [Abstract][Full Text] [Related]
19. Checkpoint inhibitor-based salvage regimens prior to autologous stem cell transplant improve event-free survival in relapsed/refractory classic Hodgkin lymphoma.
Desai SH; Spinner MA; David K; Bachanova V; Goyal G; Kahl B; Dorritie K; Azzi J; Kenkre VP; Arai S; Chang C; Fusco B; Sumransub N; Hatic H; Saba R; Ibrahim U; Harris EI; Shah H; Murphy J; Ansell S; Jagadish D; Orellana-Noia V; Diefenbach C; Iyenger S; Rappazzo KC; Mishra R; Choi Y; Nowakowski GS; Advani RH; Micallef IN
Am J Hematol; 2023 Mar; 98(3):464-471. PubMed ID: 36629030
[TBL] [Abstract][Full Text] [Related]
20. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.
Moskowitz CH; Nademanee A; Masszi T; Agura E; Holowiecki J; Abidi MH; Chen AI; Stiff P; Gianni AM; Carella A; Osmanov D; Bachanova V; Sweetenham J; Sureda A; Huebner D; Sievers EL; Chi A; Larsen EK; Hunder NN; Walewski J;
Lancet; 2015 May; 385(9980):1853-62. PubMed ID: 25796459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
